GSK begins Phase III study of subcutaneous Ofatumumab to treat pemphigus vulgaris

Genmab collaborator GlaxoSmithKline (GSK) has commenced the third phase of its study of subcutaneous formulation of ofatumumab, a human monoclonal antibody, to treat an autoimmune skin disorder, pemphigus vulgaris.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news